China Biologic Products (CBPO.OB) Enters into Research and Development Agreement
China Biologic Products is known as one of the leading plasma-based pharmaceutical companies in the People’s Republic of China. The young company took a major step towards catching the attention of investors on Wall Street with the announcement that on September 11, 2009 they entered into a strategic research and development agreement with the Institute of Blood Transfusion (IBT) to strengthen their research and development capabilities and manufacturing processes. IBT, which is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College, is a leading institute in China which specializes in a variety of plasma-based research…